Table 2.
Previous reports regarding digestive resection and MLN involvement in ovarian cancer
| No. of digestive resections | Types of digestive resection included | NACT n (%) | MLN evaluated on resected specimen | Positive MLN n (%) | OS & PFS | |
|---|---|---|---|---|---|---|
| O’Hanlan KA et al.5 Gynecol Oncol. (1995) | 100 | Any | N/S | 33 (33) | 24 (70) | Yes (2 years) |
| Salani R et al.6 Ann Surg Oncol. (2007) | 53 | Recto-sigmoidectomy | N/S | 39 (73) | 31 (79.4) | N/S |
| Baiocchi G et al.7 J Surg Oncol. (2011) | 50 | Any | N/S | 41 (82) | 29 (70.7) | N/S |
| Gouy S et al.8 Eur J Surg Oncol. (2012) | 52 | Any | 34 (65) | 52 (100) | 19 (37) | No (3 years) |
| Gallotta V et al.9 Ann Surg Oncol. 2014 | 148 | Recto-sigmoidectomy | 37 (25) | 102 (68.9) | 48 (47.0 ) | No (2 years) |
| Berretta R et al.10 Arch Gynecol Obstet. (2018) | 83 | Any | 16 (19.3) | 76 (91.6) | 43 (51.8) | Yes (20 months) |
| Tanaka K et al.11 Ann Surg Oncol. (2021) | 27 | Recto-sigmoidectomy | N/S for digestive resection for 85 OC patients 39 (45.8) | 27 (100) | 14 (52) | Yes |
| Our study (2023) | 77 | Any | 61 (79) | 44 (61.11) | 25 (56.) | No |
MLN, mesenteric lymph node; NAC, neoadjuvant chemotherapy; OS, overall survival; PFS, progression-free survival; N/S, not specified